Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2021 | Myeloma: where is I-O moving?

Immuno-Oncology (I-O) has rapidly advanced the myeloma field, with bispecific antibodies and immune effector cells (such as CAR-T cells and NK cells) being the two major forms of I-O. Parameswaran Hari, MBBS, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the immuno-oncology space, and where he believes the field will move. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.